DAR 100

Drug Profile

DAR 100

Alternative Names: DAR 0100

Latest Information Update: 30 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DarPharma
  • Class Antiparkinsonians; Antipsychotics
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Cerebral vasospasm; Cognition disorders; Drug abuse; Parkinson's disease

Most Recent Events

  • 03 Aug 2004 Preclinical trials in Cerebral vasospasm in USA (unspecified route)
  • 27 Jul 2004 Preclinical trials in Adult respiratory distress syndrome in USA (Inhalation)
  • 29 Jun 2004 Preclinical trials in Drug abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top